BTEE.L vs. CNDX.L
BTEE.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) and CNDX.L (iShares NASDAQ 100 UCITS ETF) are both exchange-traded funds - BTEE.L is a Health & Biotech Equities fund tracking the NASDAQ Biotechnology TR USD, while CNDX.L is a Nasdaq-100 fund tracking the NASDAQ-100 Index. Both are passively managed. Over the past 5 years, BTEE.L returned 4.70%/yr vs 17.61%/yr for CNDX.L. A 0.59 correlation means they provide meaningful diversification when combined. BTEE.L charges 0.35%/yr vs 0.33%/yr for CNDX.L.
Performance
BTEE.L vs. CNDX.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BTEE.L achieves a 4.58% return, which is significantly lower than CNDX.L's 19.65% return.
BTEE.L
- 1D
- 3.30%
- 1M
- -0.50%
- YTD
- 4.58%
- 6M
- 4.05%
- 1Y
- 41.72%
- 3Y*
- 13.12%
- 5Y*
- 4.70%
- 10Y*
- —
CNDX.L
- 1D
- -0.66%
- 1M
- 6.81%
- YTD
- 19.65%
- 6M
- 18.66%
- 1Y
- 39.29%
- 3Y*
- 27.98%
- 5Y*
- 17.61%
- 10Y*
- 21.62%
BTEE.L vs. CNDX.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 4.58% | 32.82% | -1.69% | 5.84% | -11.88% | -0.57% | 27.55% | 25.56% | -14.84% |
CNDX.L iShares NASDAQ 100 UCITS ETF | 19.65% | 19.75% | 26.45% | 56.31% | -33.45% | 27.96% | 48.33% | 38.07% | -8.33% |
Correlation
The correlation between BTEE.L and CNDX.L is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.35 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.41 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.51 |
Correlation (All Time) Calculated using the full available price history since Mar 9, 2018 | 0.59 |
Over the past year, the correlation between BTEE.L and CNDX.L has dropped to 0.35 - well below their long-term average of 0.59, suggesting their price drivers have been diverging.
BTEE.L vs. CNDX.L - Sectors Allocation Comparison
Sectors
BTEE.L
CNDX.L
Healthcare
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Financial Services
-
Industrials
-
Real Estate
-
Technology
-
Utilities
-
Healthcare
BTEE.L
CNDX.L
Basic Materials
BTEE.L
-
CNDX.L
Communication Services
BTEE.L
-
CNDX.L
Consumer Cyclical
BTEE.L
-
CNDX.L
Consumer Defensive
BTEE.L
-
CNDX.L
Energy
BTEE.L
-
CNDX.L
Financial Services
BTEE.L
-
CNDX.L
Industrials
BTEE.L
-
CNDX.L
Real Estate
BTEE.L
-
CNDX.L
Technology
BTEE.L
-
CNDX.L
Utilities
BTEE.L
-
CNDX.L
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BTEE.L vs. CNDX.L — Risk / Return Rank
BTEE.L
CNDX.L
BTEE.L vs. CNDX.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) and iShares NASDAQ 100 UCITS ETF (CNDX.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BTEE.L | CNDX.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.41 | ||
| Sortino ratioReturn per unit of downside risk | -0.49 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.43 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 5.41 | 3.61 | +1.80 |
| Martin ratioReturn relative to average drawdown | 16.70 | 13.03 | +3.67 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BTEE.L | CNDX.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.10 | 2.52 | -0.41 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | 0.84 | -0.62 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 1.07 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.30 | 1.12 | -0.82 |
Drawdowns
BTEE.L vs. CNDX.L - Drawdown Comparison
The maximum BTEE.L drawdown since its inception was -38.29%, which is greater than CNDX.L's maximum drawdown of -35.17%. Use the drawdown chart below to compare losses from any high point for BTEE.L and CNDX.L.
Loading charts...
Drawdown Indicators
| BTEE.L | CNDX.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.29% | -35.17% | -3.12% |
Max Drawdown (1Y)Largest decline over 1 year | -7.63% | -11.00% | +3.37% |
Max Drawdown (3Y)Largest decline over 3 years | -26.82% | -22.44% | -4.38% |
Max Drawdown (5Y)Largest decline over 5 years | -38.29% | -35.17% | -3.12% |
Max Drawdown (10Y)Largest decline over 10 years | — | -35.17% | — |
Current DrawdownCurrent decline from peak | -2.58% | -0.76% | -1.82% |
Average DrawdownAverage peak-to-trough decline | -13.56% | -5.30% | -8.26% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.47% | 3.07% | -0.60% |
Volatility
BTEE.L vs. CNDX.L - Volatility Comparison
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) has a higher volatility of 6.84% compared to iShares NASDAQ 100 UCITS ETF (CNDX.L) at 4.90%. This indicates that BTEE.L's price experiences larger fluctuations and is considered to be riskier than CNDX.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BTEE.L | CNDX.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.84% | 4.90% | +1.94% |
Volatility (6M)Calculated over the trailing 6-month period | 15.33% | 11.88% | +3.45% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.63% | 15.79% | +3.84% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.14% | 20.87% | +0.27% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.50% | 20.07% | +2.43% |
BTEE.L vs. CNDX.L - Expense Ratio Comparison
BTEE.L has a 0.35% expense ratio, which is higher than CNDX.L's 0.33% expense ratio.
Dividends
BTEE.L vs. CNDX.L - Dividend Comparison
BTEE.L's dividend yield for the trailing twelve months is around 0.36%, while CNDX.L has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.36% | 0.37% | 0.46% | 0.39% | 0.44% | 0.25% | 0.17% | 0.14% | 0.07% | 0.00% | 0.00% | 0.00% |
CNDX.L iShares NASDAQ 100 UCITS ETF | 0.00% | 0.00% | 0.02% | 0.05% | 0.06% | 0.03% | 0.04% | 0.07% | 0.06% | 0.30% | 0.16% | 0.16% |
Frequently Asked Questions
BTEE.L and CNDX.L have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, CNDX.L is cheaper at 0.33% per year. The better choice depends on whether you care most about return, fees, risk, or income.
CNDX.L is cheaper with a 0.33% expense ratio, compared with 0.35% for BTEE.L.
BTEE.L is categorized as Health & Biotech Equities, while CNDX.L is Nasdaq-100. BTEE.L tracks NASDAQ Biotechnology TR USD, while CNDX.L tracks NASDAQ-100 Index. Their fees differ too: 0.35% for BTEE.L and 0.33% for CNDX.L.
Find the right allocation for BTEE.L and CNDX.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer